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Ocular fibrosis leads to significant visual impairment and blindness in millions of people
worldwide, and is one of the largest areas of unmet need in clinical ophthalmology. The
antimetabolites, mitomycin C and 5-fluorouracil, are the current gold standards used primarily
to prevent fibrosis after glaucoma surgery, but have potentially blinding complications like
tissue damage, breakdown and infection. This review thus focuses on the development of
new classes of small molecule therapeutics to prevent post-surgical fibrosis in the eye,
especially in the context of glaucoma filtration surgery. We discuss recent advances and
innovations in ophthalmic wound healing research, including antibodies, RNAi, gene therapy,
nanoparticles, liposomes, dendrimers, proteoglycans and small molecule inhibitors. We also
review the challenges involved in terms of drug delivery, duration of action and potential
toxicity of new anti-fibrotic agents in the eye.
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Fibrosis & wound healing
Fibrosis and scarring are involved in the path-
ogenesis or failure of treatment of virtually all
the major blinding diseases. Glaucoma is the
second leading cause of blindness in the world.
By 2020, its prevalence is estimated to reach
around 79.6 million people worldwide, with
more than 11 million individuals suffering
from bilateral blindness [1]. Glaucoma filtra-
tion surgery is the mainstay of surgical treat-
ment for medically uncontrolled glaucoma.
Even with new surgical techniques, postopera-
tive scarring remains a critical determinant of
the long-term surgical outcome and intraocular
pressure after drainage surgery [2]. The antime-
tabolites, mitomycin C (MMC) and 5-fluoro-
uracil (5-FU), have improved the surgical
outcome of glaucoma filtration surgery, but
lead to non-specific cytotoxicity and the risk
of sight-threatening complications like tissue
damage, breakdown and infection. In addition,
some patients still scar and fail surgery despite
antimetabolite therapy. There is thus a large
unmet need to develop new anti-fibrotic thera-
peutics to prevent scarring and post-surgical
fibrosis in the eye.
Wound healing is a complex multifactorial
process consisting of a cascade of overlapping
events, including hemostasis, inflammation, cell
proliferation and tissue remodeling (FIGURE 1).
After injury, hemostasis takes place, and blood
and fibrin clots are formed to reduce blood loss.
This leads to an inflammatory phase where neu-
trophils, macrophages and lymphocytes are
attracted to the wound site as part of the
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immune response. This is then followed by a proliferative phase
where fibroblasts are activated to lay down extracellular matrix,
leading to re-epithelialization, angiogenesis and granulation tissue
formation. The final step is tissue remodeling and scar formation,
and matrix metalloproteinases (MMPs) play an important role in
the process.
In this review, we focus on the development of novel small
molecule therapeutics to modulate ophthalmic wound healing,
especially in the context of post-surgical scarring after glaucoma
filtration surgery. We discuss the recent advances and also the
pitfalls of different types of therapeutic molecules, including
antibodies, RNAi, gene therapy, nanoparticles, liposomes, den-
drimers, proteoglycans and small molecule inhibitors, to pre-
vent scarring and promote healthy cell regeneration in the eye.
Antibodies
Monoclonal antibodies are only a few nanometers in size, but
currently represent one of the largest classes of therapeutic mole-
cules. Unlike antimetabolites, one of the key advantages of an
antibody is its target specificity in ocular therapeutics (TABLE 1).
TGF-b plays a pivotal role in wound healing as it increases fibro-
blast proliferation [3], controls extracellular matrix synthesis [4]
and accelerates myofibroblast differentiation [5]. Our group has
previously shown that subconjunctival monoclonal antibody to
TGF-b2 decreased conjunctival scarring in an experimental
model of glaucoma surgery [6], but did not significantly prolong
bleb survival after glaucoma filtration surgery in a randomized
clinical trial (RCT) [7]. However, it is likely that the doses used
were not high enough for a sufficiently long period of tissue expo-
sure, and that a prolonged or slow release dosing regimen might
have been required [8]. Furthermore, it is likely that a broader
coverage of the different isoforms might also have been necessary.
Connective tissue growth factor (CTGF) is a key downstream
mediator of TGF-b-induced fibrosis, and can accelerate fibroblast
proliferation and secretion of extracellular matrix [9]. Wang et al.
have shown that subconjunctival injection of a CTGF antibody
can maintain larger bleb areas and lower
intraocular pressures in a rabbit model of
trabeculectomy [10]. Yuan et al. have also
found that CTGF is overexpressed in fil-
tration blebs, suggesting that CTGF might
play an important role in the process of
wound healing after trabeculectomy [11].
VEGF is a crucial mediator of angiogen-
esis, and stimulates both fibroblasts and
endothelial cells in wound healing [12,13].
Bevacizumab is a recombinant humanized
monoclonal antibody against VEGF, and
several studies have shown that it decreases
scar formation and prolongs bleb survival
after experimental glaucoma filtration sur-
gery [12,14,15]. However, Rodrı´guez-
Agirretxe et al. reported that combined
MMC and bevacizumab implants
decreased intraocular pressure to a lesser
extent than MMC alone, and that bevacizumab could interact
with MMC [16]. In the first RCT, Nilforushan et al. found that
the MMC group had better intraocular pressure control but simi-
lar bleb morphology to the subconjunctival bevacizumab
group [17], and other studies have also suggested that the antibody
alone is currently less effective than MMC [18]. Vandewalle et al.
recently reported that perioperative administration of intracam-
eral bevacizumab significantly reduced the need for needling
interventions, and led to a higher success rate after trabeculec-
tomy [19]. Further RCTs are needed to investigate the best way of
using anti-VEGF therapies in glaucoma surgery, and the optimal
doses and combinations with other anti-scarring agents.
PlGF is a VEGF-homolog that binds to VEGF-R1 and acts
on pathological angiogenesis and inflammation [20]. Bergen et al.
showed that intracameral injection of a monoclonal PlGF anti-
body increased bleb area and survival in a mouse model of glau-
coma surgery [21]. Furthermore, anti-PlGF treatment seemed to
be more effective than anti-VEGF-R2 treatment in improving
the surgical outcome, possibly due to its additional effect
on inflammation.
Lysyl oxidase (LOX) is another important class of enzymes
that catalyses the covalent crosslinking of collagens and elastin in
the extracellular matrix [22]. Bergen et al. have found that LOX
and LOX-like 2 (LOXL2) are both upregulated in Tenon’s cap-
sule [23]. The authors also showed that targeting LOXL2 with an
inhibitory monoclonal antibody, GS-607601, reduced pathologi-
cal angiogenesis, inflammation, fibrosis and prolonged bleb sur-
vival in a rabbit model of trabeculectomy [23].
Integrins are protein heterodimers consisting of non-covalently
associated a- and b-subunits, and the adhesive interactions medi-
ated by integrins are necessary for cell proliferation [24].
Paikal et al. reported that different integrin antibodies inhibited
the attachment and proliferation of human Tenon’s fibroblasts
in vitro [25]. Further in vivo studies are needed to determine
whether integrin antibodies can significantly limit scar formation
after glaucoma surgery without significant toxicity.
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Figure 1. The general phases of wound healing.
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siRNA & shRNA therapy
RNAi is another promising therapeutic approach as it can be
used to silence the expression of unwanted genes in fibrosis
(TABLE 2). RNAi is mediated by siRNAs, shRNAs and miRNAs.
siRNAs are small double-stranded exogeneous RNA molecules
(20–25 base pairs) [26], and shRNAs are short sequences of
RNA with a tight hairpin turn that can be used in post-
transcriptional gene silencing [27].
Transcription factors are key molecules that regulate gene
expression by controlling the transcription of DNA into mes-
senger RNA. NF-kB is a transcription factor that activates
fibroblasts and is regulated by IkB kinase subunit b.
Duan et al. showed that siRNAs targeting IkB kinase subunit b
effectively downregulated NF-kB in human Tenon’s fibroblasts
and suppressed fibroblast proliferation [28].
Growth factors, especially TGF-b, also play a pivotal role in
ocular fibrosis. Nakamura et al. reported that siRNAs efficiently
knocked down TGF-bRII expression in human corneal fibro-
blasts, and that direct ocular application of TGF-bRII siRNAs
could be used to decrease scarring in the subconjunctival space
in the mouse [29].
Cell cycle regulators also represent potential anti-fibrotic gene
therapeutic targets. S phase kinase-interacting protein 2 is a key cell
cycle regulator that targets p27. Wang et al. found that siRNA
silencing of S phase kinase-interacting protein 2 decreased prolifera-
tion and cell viability in rabbit Tenon’s fibroblasts, and had poten-
tial as an anti-scarring therapy in glaucoma filtration surgery [30].
Proteins are also important components of the extracellular
matrix in the eye. Seet et al. showed that knocking down
secreted protein, acidic, rich in cysteine (SPARC) impaired
contraction in human Tenon’s fibroblasts and reduced the
expression of profibrotic genes, namely collagen I, MMP-2,
MMP-9, MMP-14, IL-8 and TGF-b [31]. Yuan et al. found
that shRNAs effectively suppressed the expression of keratoepi-
thelin and myocilin in trabecular meshwork cells [32]. Comes
and Borra´s also reported that siRNAs effectively silenced Matrix
GLA protein expression in trabecular meshwork cells, and that
intracameral delivery of siRNAs could become a future drug
delivery technique in glaucoma [33].
The success of siRNA therapeutics will depend largely on the
efficient ocular delivery of siRNAs. In a Phase I study,
Kaiser et al. showed that intravitreal injections of
siRNA-027 were well tolerated in the eye, and led to an improve-
ment in visual acuity and foveal thickness in patients with wet
age-related macular degeneration [34]. Ocular delivery of naked
siRNAs is, however, unlikely to be sufficient in ocular fibrosis as
siRNAs are not permeable across cell membranes and are not
resistant against enzymatic degradation. Viral delivery systems,
including adenoviral vectors [35] and lentiviral vectors [36], have
shown good transfection efficacy. Non-viral delivery systems
have also been used, including cationic liposomes [37] and cat-
ionic copolymers like CS-g-(PEI-b-mPEG) [28].
miRNA therapy
There is now increasing evidence of the key role of miRNAs in
fibrosis (TABLE 2). miRNAs are small single-stranded endogenous
RNA transcripts (21–25 nucleotides) that are involved in
post-transcriptional gene modulation [38]. One of the most studied
Table 1. Summary of properties of different therapeutic molecules in ocular fibrosis.
Therapeutic
molecule
Size Specificity Tested drug
delivery route
Duration of action Toxicity (potential
side effects)
Antibody 10–9 m High Subconjunctival
Intracameral
>30 days (end of study) Low (immunogenic)
siRNA 20–25 base
pairs
High Subconjunctival
Intravitreal
>14 days (end of study) Low (off-target effect,
immunogenic)
miRNA 21–25
nucleotides
High Locked nucleic acid Decreases fibroblast
activity (in vitro)
Low
Viral vector 10-9 m High Subconjunctival
Intravitreal
>30 days (end of study) Moderate (oncogenic,
immunogenic)
Nanoparticle 10–9 m Moderate Topical
Subconjunctival
Intravitreal
>42 days (end of study) Low (cytotoxic,
genotoxic)
Liposome 10–6 m Low Subconjunctival
Intravitreal
>14 days (end of study) Low
Drug inhibitor 10–6–10–9 m Low Topical
Subconjunctival
Intravitreal
>30 days (end of study) Variable (cytotoxic)
Proteoglycan 10–3 Da Low Subconjunctival
Intravitreal
>14 days (end of study) Low
Dendrimer 10–9 m Low Subconjunctival 28 days (maximal effect) Low
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miRNAs in fibrosis is miR-29, and downregulation of miR-29 has
been linked to tissue scarring in various body systems, namely car-
diac fibrosis [39], pulmonary fibrosis [40], liver fibrosis [41], renal
fibrosis [42], skin fibrosis [43] and fibrosis in cancer [44,45].
Li et al. showed that miR-29b suppressed collagen type I
gene expression and was significantly downregulated in
TGF-b1-activated human Tenon’s fibroblasts [46]. The authors
also reported that increasing intracellular miR-29b expression,
by exogenous miR-29b delivery, effectively decreased fibroblast
activity in vitro [46].
In addition, Luna et al. showed that miR-29b downregulated
the expression of multiple genes involved in the synthesis of
extracellular matrix in human trabecular meshwork cells, and
decreased cell cytotoxicity in the presence of chronic oxidative
stress [47]. Increasing miR-29b expression might thus represent
a therapeutic approach to limit extracellular matrix deposition,
prevent trabecular meshwork cell loss and facilitate aqueous
humor outflow in glaucoma [47].
miR-29 is one of the well-described TGF-b-associated miR-
NAs involved in fibrosis [39,40]. miR-29 regulates multiple genes
encoding for extracellular matrix proteins, including COL1A1,
COL1A2, COL3A1, FBN1, ELN and SPARC [47,48]. Some level
of cross-talk has also been reported between miR-29 and
TGF-b in trabecular meshwork cells, suggesting that
miR-29 could represent an important modulator of TGF-b in
aqueous outflow in glaucoma [49].
The tumor suppressor gene p53 enhances the rate of tran-
scription of several genes that regulate cell-cycle arrest and apo-
ptosis [50]. Park et al. have shown that miR-29 positively
regulates p53, and might thus inhibit fibroblast proliferation in
conjunctival scarring [51]. The authors have also found that
miR-29 directly suppresses CDC42 (a Rho family GTPase)
and p85a (the regulatory subunit of PI3K) [51]. As the Rho/
MRTF/SRF (Myocardin related transcription factor/Serum
response factor) pathway is increasingly being associated with
fibrosis [52,53], upregulating miR-29 could also decrease ocular
scarring by suppressing the Rho-actin pathway. Although speci-
ficity has been thought to be an advantage in many clinical sit-
uations, this overlap of activity may be advantageous in
scarring inhibition due to the overlap of multiple pathways.
Other miRNAs that have been identified as key triggers of
fibrosis driven by TGF-b include miR-21 [54,55], miR-192 [56],
miR-216a and miR-217 [57]. miR-21 is expressed in the lungs
of patients with idiopathic pulmonary fibrosis. Mice treated
with miR-21 antisense probes were also protected from
bleomycin-induced pulmonary fibrosis [54], and cardiac fibrosis
induced by pressure overload [55]. miR-21 is thought to pro-
mote fibrosis by regulating TGF-b1 and MAPK signaling in
activated myofibroblasts.
Future research will focus on the development and effective
ocular delivery of miRNA-based therapies to prevent scarring
in the eye. miR-29 mimics to increase miR-29 expression, and
pharmacological inhibitors to prevent the downregulation of
miR-29 expression, both have therapeutic potential. Locked
nucleic acid-modified oligonucleotides are single-stranded bicy-
clic RNA analogs that irreversibly bind to miRNAs [58], and
could potentially be used for the ocular delivery of miRNA
therapies. Miravirsen is a locked nucleic acid that sequesters
miR-122, and provides proof-of-concept of the efficacy of
miRNA therapy in human disease [59].
Viral gene transfer & gene therapy
Instead of blocking unwanted mRNA expression like siRNAs,
shRNAs and miRNAs, other methods of gene therapy involve
increasing the expression of inhibitory genes on the cell
Table 2. Tested anti-fibrotic gene therapeutic
targets in the eye.
Therapeutic
target
Cell type Delivery
Transcription factors
NF-kB Human Tenon’s fibroblasts siRNA
E2F Human Tenon’s fibroblasts Hemagglutinating
virus of Japan
Cell cycle regulators
p53 Human Tenon’s fibroblasts Recombinant
adenovirus
p21 Rabbit Tenon’s fibroblasts Recombinant
adenovirus
Skp2/p27 Rabbit Tenon’s fibroblasts siRNA
Growth factors
TGF-b Human corneal fibroblasts siRNA
Proteins
Keratoepithelin Human trabecular
meshwork cells
shRNA
Myocilin Human trabecular
meshwork cells
shRNA
SPARC Human Tenon’s fibroblasts siRNA
Matrix GLA
protein
Human trabecular
meshwork cells
siRNA
miRNAs
miR-29b Human Tenon’s fibroblasts miRNA
miR-29b Human trabecular
meshwork cells
miRNA
Others
Smad7 Human conjunctival
fibroblasts
Recombinant
adenovirus
p38MAPK Mouse subconjunctival
fibroblasts
Adenovirus
Cytosine
deaminase
Rabbit Tenon’s fibroblasts Recombinant
adenovirus
SPARC: Secreted protein, acidic, rich in cysteine.
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cycle (TABLE 2). Human p53 is a tumor suppressor gene that
plays a key role in arresting cell cycle progression to allow
DNA repair, or to induce apoptosis if the damage is too exten-
sive [50]. Using a recombinant adenovirus (rAd) for p53,
Johnson et al. induced overexpression of p53 in human
Tenon’s fibroblasts, and significantly inhibited fibroblast prolif-
eration and DNA synthesis [60].
Perkins et al. also showed that a rAd containing the
p21 gene, which is a crucial downstream effector of p53, inhib-
ited the proliferation of rabbit Tenon’s fibroblasts and per-
formed similarly to MMC in terms of decrease in intraocular
pressure [61]. In a primate model of glaucoma surgery,
Heatley et al. found that rAd.p21 gene therapy prevented con-
junctival scarring and achieved even better intraocular pressure
control than the MMC-treated group [62]. Both rAd.p21 gene
therapy studies did not report any of the tissue complications
seen with MMC treatment.
In addition, Akimoto et al. used a rAd containing the cytosine
deaminase gene to convert the pro-drug 5-fluorocytosine into
5-FU in glaucoma surgery [63]. In an earlier study, the same
authors reported that blocking the transcription factor E2F
using the hemagglutinating virus of Japan on cationic liposomes
inhibited fibroblast proliferation in glaucoma surgery [64].
Furthermore, Yamanaka et al. reported that a rAd expressing
Smad7 blocked the expression of Smad2/3 and suppressed colla-
gen type I, a-smooth muscle actin and VEGF in human conjunc-
tival fibroblasts [65]. The authors have thus suggested that
Smad7 gene transfer could become an effective strategy to prevent
excessive conjunctival scarring in glaucoma filtration surgery.
Yamanaka et al. also showed that adenoviral gene transfer of
a dominant negative p38MAPK decreased conjunctival fibrosis
both in vitro and in vivo [66]. They found that p38MAPK gene
transfer blocked the TGF-b increase in collagen type I expres-
sion, CTGF and the monocyte/macrophage chemoattractant
protein-1. The authors have thus suggested that p38MAPK
inhibition could become a future anti-scarring therapy in glau-
coma filtration surgery.
A difficult challenge with gene therapy remains the delivery
of the gene into the target cell. The main disadvantage of non-
viral methods, including ballistic DNA injections [67] and lipo-
somes [68], is that the gene expression is short-lived and lasts
only a few days. Viral methods achieve longer gene expression,
and adenovirus is a double-strain DNA virus shown to be an
efficient vector for gene transfer in ocular cells [69]. There is,
however, a rare but inherent risk of mutagenesis with the use
of viral vectors, and at least two cases of lymphoproliferative
disorders related to gene therapy have been described [70].
Nanoparticles
Nanotechnology and nanoparticle research currently represent
an area of great research interest due to its translational potential
in a wide variety of scientific fields. Nanoparticles typically range
in size between 1 and 100 nm (TABLE 1), and several research
groups worldwide are developing nanoparticles that could be
used to modulate wound healing in the eye. Nanoparticles have
several key advantages: a large surface area, for example, a stan-
dard teaspoon of 10-nm diameter silica nanoparticles has more
surface area than a dozen double-sized tennis courts, good pene-
tration and improved bioavailability by enhancing aqueous solu-
bility and targeted drug delivery to a specific location in the eye.
Using the rabbit model of glaucoma filtration surgery,
Butler et al. showed that topical silver nanoparticles (Ag-NPs)
achieved an improved and sustained reduction in intraocular
pressure, and led to blebs with decreased fibrosis and ischemia
compared with MMC [71]. Ag-NPs have also been shown to
accelerate wound healing after skin burns, with decreased scar
tissue formation and anti-inflammatory effects [72]. Ag-NPs
have a good safety profile in the eye [73], but large particle
diameters and higher concentrations have been associated with
increased cytotoxicity and genotoxicity [74].
SPARC silencing has been shown to decrease collagen gel
contraction in vitro [31], and to prolong bleb survival in a
mouse model of glaucoma filtration surgery [75]. Tan et al. have
shown that layer-by-layer nanoparticles could be used as an
efficient delivery vehicle for SPARC silencing and siRNA thera-
peutics [76]. No toxic side effects were observed with the layer-
by-layer nanoparticles.
Shao et al. have also reported that low-density lipoprotein
(LDL)-MMC-chitosan nanoparticles could be used as a target
drug delivery system to specifically bind to LDL receptors on
activated human Tenon’s fibroblasts [77]. The LDL-MMC-chi-
tosan nanoparticles are associated with high selective targeting,
good biocompatibility, low immunogenicity, decreased toxicity
to normal cells and increased effectiveness of the anti-scarring
agent MMC in glaucoma filtration surgery.
In addition, Santos et al. showed that subconjunctival
administration of nanosized complexes of antisense TGF-b2
phosphorothioate oligonucleotides with polyethylenimine
(PEI) increased intracellular penetration of TGF-b2 antisense
oligonucleotides in conjunctival cells [78]. The authors also
found that the sustained release of these nanosized complexes
significantly improved bleb survival in a rabbit model of
trabeculectomy [78].
Duan et al. also reported that cationic nano-copolymers
combined with IKKb targeting siRNA [CS-g-(PEI-b-mPEG)/
IKKb-siRNA] inhibited fibroblast proliferation in vitro [28].
Ye et al. showed that subconjunctival injection of these nano-
copolymers decreased subconjunctival scarring and increased
bleb survival in a monkey model of glaucoma filtration sur-
gery [79]. The authors also found that the cationic nano-
copolymers were well tolerated and non-toxic in the eye.
Liposomes
There is now increasing research in using liposomes as a drug
delivery system for anti-scarring agents in the eye. Liposomes
are small composite structures composed of a lamellar phase
lipid bilayer, and vary in size between low to tens of
micrometers (TABLE 1). Peng et al. showed that subconjunctival
injections of liposomes containing homoharringtonine, an alka-
loid and protein synthesis inhibitor, reduced the intraocular
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pressure and inhibited scarring in a rabbit model of
trabeculectomy [80].
Simmons et al. also developed a liposomal delivery system for
5-FU to prolong the ocular levels of the drug in glaucoma filtra-
tion surgery [81]. They found that liposomal 5-FU prolonged the
scleral and conjunctival concentrations of the drug in rabbits,
while reducing the peak ocular concentrations. Liposomal 5-FU
could thus help improve the surgical outcome of glaucoma sur-
gery, as well as decrease the risk of ocular side effects.
Daunorubicin is an anthracycline anti-cancer drug that is
used to block DNA synthesis. Varma et al. showed that dauno-
rubicin was safe and effective at lowering intraocular pressure
in glaucoma filtration surgery [82]. Shinohara et al. also showed
that daunorubicin encapsulated in empty liposomes was effec-
tive in preventing proliferative vitreoretinopathy in a rabbit
model [83]. The authors did not report any adverse side effects
with liposomal daunorubicin.
Tilleul et al. also showed that a liposome formulation of the
anti-mitotic mitoxantrone reduced intraocular pressure and
improved the surgical outcome of glaucoma surgery, when
injected subconjunctivally at the end of surgery in rabbits [84].
The effect of mitoxantrone in liposome formulation was similar
to MMC application, and decreased the occurrence of corneal
opacity compared with those treated with mitoxantrone
in solution.
Dendrimers & proteoglycans
Other classes of therapeutic molecules that have been developed
to modulate ophthalmic wound healing are dendrimers and
proteoglycans (TABLE 1). Dendrimers are hyperbranched nanomole-
cules that can be chemically synthesized to have precise structural
characteristics. Our group has shown that the dendrimer glucos-
amine [D(+)-glucosamine] and dendrimer glucosamine 6-sulfate
[D(+)-glucosamine 6-sulfate] have immunomodulatory and anti-
angiogenic properties respectively, and that their combined use
significantly increased the long-term surgical success in a rabbit
model of glaucoma filtration surgery [85]. We did not observe
any local or systemic side effects with the dendrimer drugs.
Decorin is a small proteoglycan that binds to TGF-b and can
inhibit its activity in wound healing [86]. Grisanti et al. reported
that decorin significantly decreased intraocular pressure and
post-surgical fibrosis in a rabbit model of trabeculectomy [87].
Decorin was also well tolerated in the experimental model of
glaucoma filtration surgery, and no adverse effects, such as
inflammation or blurring of the optical media, were observed.
Small molecule inhibitors & drugs
Small molecule inhibitors and drugs are showing a lot of
potential as effective anti-fibrotic agents for the eye (TABLE 1).
Honjo et al. showed that the Rho-associated protein kinase
(ROCK) inhibitor, Y-27632, prevented fibroblast-mediated
matrix contraction in vitro, and increased bleb survival in a rab-
bit model of glaucoma filtration surgery [88]. There were no
adverse side effects observed with the Y-27632 inhibitor.
ROCK inhibitors may block TGF-b-induced scarring by
downregulating pathways generating mechanical tension, and
thus improve the long-term success of glaucoma surgery. Inoue
and Tanihara have also shown that a ROCK inhibitor signifi-
cantly decreased intraocular pressure in vivo by directly affect-
ing the trabecular meshwork and Schlemm’s canal [89].
Rac1 is a small Rho GTPase involved in regulating cytoskele-
tal organization, and plays an important role in protrusive activ-
ity and wound healing [90]. Xu et al. have shown that
Rac1 inhibition reverses the phenotype of fibrotic fibroblasts in
the skin [91]. Our group has previously shown that the
Rac1 inhibitor, NSC23766, efficiently inhibited conjunctival tis-
sue and fibroblast-mediated matrix contraction [92].
NSC23766 did not cause any significant toxicity, and was associ-
ated with reduced MMP1 expression during matrix contraction.
In a high-throughput screen, Evelyn et al. have also identified
the small molecule inhibitor CCG-1423 as being more effective
in reducing MRTF/SRF-regulated gene transcriptional signaling
than ROCK inhibitors [93]. Bell et al. have more recently opti-
mized a second-generation inhibitor, CCG-203971, that is
more potent and less cytotoxic than CCG-1423 [94]. CCG
inhibitors have shown efficacy in decreasing fibrosis in the
skin [95] and colon [96], and it will be interesting to see their
effects on wound healing in the eye.
MMPs are a large family of calcium-dependent zinc-contain-
ing endopeptidases that play a crucial role in tissue remodeling
and degradation of collagens and extracellular matrix [97–99].
Our group has previously shown that MMP inhibition
decreased matrix contraction and collagen production in vitro
[98], as well as scarring in a rabbit model of glaucoma filtration
surgery [97,99].
Furthermore, inhibitors for activin receptor-like kinase
5 (ALK5), also known as TGF-b receptor type I, have been
studied in ocular fibrosis. Sapitro et al. reported that the
ALK5 inhibitor, SB-505124, suppressed TGF-b activity and
promoted bleb survival in a rabbit model of trabeculec-
tomy [100]. Xiao et al. also showed that the ALK5 inhibitor,
SB-431542, decreased post-surgical scarring and fibrosis after
experimental glaucoma filtration surgery [101].
Pirfenidone (PFD) is an interesting small molecule drug that
downregulates a series of key profibrotic cytokines and growth
factors like TGF-b [102]. Zhong et al. showed that postoperative
topical PFD was safe and improved bleb survival in a rabbit
model of glaucoma filtration surgery [103]. Other authors have
also found that PFD decreased scarring and improved wound
healing after corneal burns [104], strabismus surgery [105] and
proliferative vitreoretinopathy [106].
Expert commentary
To date, there has been significant progress made in the devel-
opment of small molecule therapeutics to modulate ophthalmic
wound healing using different approaches (FIGURE 2). Given that
fibrosis-related events play a part in most of the blinding dis-
eases in the world and also account for over 40% of all deaths,
this represents one of the largest areas of unmet need in clinical
ophthalmology and clinical medicine.
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BOX 1 describes the properties of the ideal anti-scarring agent
or combination of agent(s). Antibody therapeutics is currently a
fast growing area of research, and there have also been major
advances in the field of gene modulating therapies, nanopar-
ticles, liposomes, dendrimers and small molecule inhibitors in
ocular fibrosis. Clinical trials using antisense oligonucleotides
and ribozymes have so far proved to be disappointing, but
RNAi is more potent than antisense oligonucleotides [107].
The eye has the distinct advantage of being a closed com-
partment where small molecule therapeutics can be injected
close to the target tissues, thus minimizing the risks of side
effects to the rest of the body. This includes both the intraocu-
lar and subconjunctival space after glaucoma surgery that is eas-
ily accessible in the outpatient clinical setting. Drug delivery
and duration of action remain major hurdles in the develop-
ment of novel anti-scarring therapies. New slow release drug
delivery systems, like ocular tablets and in situ gels, are being
developed to decrease the need for multiple injections in glau-
coma surgery [108]. RNAi formulations (RNAi + delivery sys-
tem) are also being designed to increase the cellular uptake, to
protect against enzymatic degradation and to permit the long-
term delivery of RNAi therapies [26].
Another key challenge with new anti-fibrotic agents is their
potential toxicity in humans. Several small molecule inhibitors
have shown promising results as anti-fibrotic agents, but their
ocular toxicity have yet to be fully investigated. Viral vector
delivery systems have also shown high transfection efficacy, but
is limited by the risks of mutagenesis and host immunity [109].
The unselective silencing of additional genes represents another
potential side effect with RNAi therapeutics, and a possible
solution might be to chemically modify one or both of the
siRNA strands to minimize the risk of off-target effects [110].
Five-year view
It is well established that some group of patients scar much
more than others. However, there is a current lack of reliable
biomarkers to stratify the risk of scarring and post-surgical fibro-
sis in the eye. In the next 5 years, the hope is that advances in
genotyping and phenotyping, using modern tissue biomarkers
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Figure 2. Schematic diagram summarizing the different therapeutic molecules in ocular fibrosis and their modes of action.
MRTF: Myocardin-related transcription factor; SRF: Serum response factor.
Box 1. Properties of the ideal anti-scarring agent(s).
• Effective anti-fibrotic effects, but allows some healing (e.g.,
maintains tissue flow ~10 mmHg after glaucoma surgery).
• High specificity for target(s), but able to adequately suppress
multiple pathways that constitute complex fibrosis.
• Safe to handle.
• Short initial delivery method, ideally at the time of surgery.
• Long duration of action, ideally >10 years (or easily delivered
at intermittent intervals, e.g. yearly).
• Inexpensive and easily mass produced.
• Minimal toxicity.
• Applicable in many different situations in the eye and body.
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and high-resolution real-time in vivo imaging techniques, will
help to identify the groups of patients that would scar more
aggressively, and thus help to develop a more personalized and
stratified approach in anti-fibrotic ocular therapeutics.
Although fibroblasts underlie the scarring process after glau-
coma filtration surgery, there are also other cell types, like inflam-
matory cells, which play an important role in the wound healing
process. The aim of future research will thus be to develop com-
bination therapies targeting several pathways that would be more
efficacious than monotherapies, especially in the high-risk
groups. The ability to predict the risk of scarring and to tailor the
anti-fibrotic treatment regimen to each individual patient will be
an extremely useful tool clinically to prevent undertreating, or
exposing patients to unnecessary treatments with potential side
effects. Furthermore, development of new therapies in combina-
tion with surgical devices, where scarring is currently still a signif-
icant long-term problem, further increases both the challenges
and the gains to be made in clinical outcomes in many pathologi-
cal situations affecting the eye and other body organs.
Finally, apart from a few studies on anti-TGF-b and anti-
VEGF therapies, there is a current lack of well-designed
randomized controlled trials to compare the efficacy and safety of
different therapeutic molecules in ocular fibrosis. Similar to cancer
therapeutics, more refined human studies with long-term follow-
ups are needed, alongside carefully chosen comparative control
groups. In addition, a combination of agents may afford us much
better control of the scarring process, as has been the case in can-
cer therapy. The ultimate goal in the future will be to modulate
the wound healing process in each patient toward a more regener-
ative repair process with no scarring, possibly combined with new
bioengineered devices. This will allow us to achieve a new genera-
tion of outcome goals not previously possible. This includes auda-
cious goals such as our 10, 10, 10 target for glaucoma surgery: a
postoperative intraocular pressure of 10 mmHg, carried out in
10 minutes and lasting for at least 10 years. New therapies to pre-
vent long-term scarring, together with new bioengineering tech-
nologies, will help to make this possible in the future.
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Key issues
• Fibrosis and scarring are responsible for the pathogenesis or failure of treatment of all the major blinding diseases, with postop-
erative wound healing responses posing a major problem for most ocular surgery on a worldwide scale.
• Fibrosis prevention is one of the largest areas of unmet need in clinical medicine.
• Antibodies are a fast growing class of therapeutics and hold a lot of potential in the development of new anti-fibrotic treatments.
• Gene modulation and gene therapy represent an exciting and innovative approach to prevent scarring and post-surgical fibrosis
in the eye.
• There have also been significant advances in small molecule therapeutics, including nanoparticles, liposomes, proteoglycans,
dendrimers and inhibitors, to modulate ophthalmic wound healing.
• Optimal drug delivery and potential ocular toxicity remain major challenges in the development of effective anti-fibrotic
therapies.
• Future research will focus on developing a more personalized and stratified approach in anti-fibrotic ocular therapeutics,
combinations of therapies and the need for well-designed randomized controlled human trials.
• New therapies to prevent scarring together with new bioengineering technologies will also allow far better long-term clinical
outcomes in the future.
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